13F-HR 1 form13f_1259957-ridgeback.txt FORM 13F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2007 --------------------------------- Check here if Amendment |_|; Amendment Number: ------------------------------- This Amendment (Check only one.): |_| is a restatement. |_| adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Ridgeback Capital Investments L.P. ------------------------------------ Address: 430 Park Avenue, 12th Floor ------------------------------------ New York, New York 10022 ------------------------------------ Form 13F File Number: 28-_____ The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Ridgeback Capital Investments Ltd., as General Partner, by Bud Holman ------------------------------------ Title: Director ------------------------------------ Phone: (212) 808-7729 ------------------------------------ Signature, Place, and Date of Signing: /s/ Bud Holman New York, New York February 14, 2008 ---------------------------- ------------------------ ------------------- [Signature] [City, State] [Date] Report Type (Check only one.): |X| 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) |_| 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) |_| 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 3 ------------- Form 13F Information Table Entry Total: 29 ------------- Form 13F Information Table Value Total: $612,107 ------------- (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Form 13F File Number Name 1 28- 12280 Ridgeback Capital Management LLC --------------- ----------------------------------- 2 28- 12278 Wayne Holman --------------- ----------------------------------- 3 28- 12277 Ridgeback Capital Investments Ltd. --------------- ----------------------------------- FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 -------- -------- -------- -------- -------- ----------- -------- --------------------- NAME OF ISSUER TITLE CUSIP VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY OF CLASS (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE ---------------- -------- -------- -------- -------- --- ----- ----------- -------- ---- ------ -------- Acorda Common Stock 00484M106 $73,099 3,328,762 SH Sole 1,2 3,328,762 Therapeutics Inc. Allscripts Common Stock 01988P108 $17,328 892,300 SH Sole 1,2 892,300 Healthcare Solutions, Inc. Altus Common Stock 02216N105 $432 83,397 SH Sole 1,2 83,397 Pharmaceuticals Inc. AP Pharma Inc. Common Stock 00202J203 $1,158 732,891 SH Sole 1,2 732,891 Avigen Inc. Common Stock 053690103 $5,328 1,253,707 SH Sole 1,2 1,253,707 Bentley Common Stock 082657107 $2,228 147,663 SH Sole 1,2 147,663 Pharmaceuticals Inc. Biodel Inc. Common Stock 09064M105 $42,929 1,848,000 SH Sole 1,2 1,848,000 Biodelivery Common Stock 09060J106 $1,000 341,442 SH Sole 1,2 341,442 Sciences Int'l Inc. Chelsea Common Stock 163428105 $21,520 2,927,942 SH Sole 1,2 2,927,942 Therapeutics Int'l, Ltd. Cyberonics Inc. Common Stock 23251P102 $14,483 1,100,516 SH Sole 1,2 1,100,516 Human Genome Common Stock 444903108 $67,860 6,500,000 SH Sole 1,2 6,500,000 Sciences Inc. Incyte Corp. Common Stock 45337C102 $9,902 985,300 SH Sole 1,2 985,300 Isolagen Inc. Common Stock 46488N103 $6,915 2,754,900 SH Sole 1,2 2,754,900 Maxygen Inc. Common Stock 577776107 $8,628 1,074,526 SH Sole 1,2 1,074,526 Medarex Inc. Common Stock 583916101 $4,210 404,000 SH Sole 1,2 404,000 Momenta Common Stock 60877T100 $12,601 1,764,826 SH Sole 1,2 1,764,826 Pharmaceuticals Inc.
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 -------- -------- -------- -------- -------- ----------- -------- --------------------- NAME OF ISSUER TITLE CUSIP VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY OF CLASS (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE ---------------- -------- -------- -------- -------- --- ----- ----------- -------- ---- ------ -------- Momenta Common Stock 60877T100 $485 3,766 SH CALL Sole 1,2 Pharmaceuticals Inc. Momenta Common Stock 60877T100 ($77) (1,000) SH PUT Sole 1,2 Pharmaceuticals Inc. Monogram Common Stock 60975U108 $568 400,000 SH Sole 1,2 400,000 Inc. Biosciences Nektar Common Stock 640268108 $30,262 4,510,000 SH Sole 1,2 4,510,000 Therapeutics Pharmasset Inc. Common Stock 71715N106 $6,750 500,000 SH Sole 1,2 500,000 Pharmion Corp. Common Stock 71715B409 $33,645 535,241 SH Sole 1,2 535,241 Pipex Pharmaceuticals, Common Stock 724153200 $9,506 1,856,565 SH Sole 1,2 1,856,565 Inc. Poniard Common Stock 732449301 $2,377 539,000 SH Sole 1,2 539,000 Pharmaceuticals Inc. Regeneron Common Stock 75886F107 $19,924 825,000 SH Sole 1,2 825,000 Pharmaceuticals Inc. Savient Common Stock 80517Q100 $49,271 2,145,000 SH Sole 1,2 2,145,000 Pharmaceuticals Inc. Vivus Inc. Common Stock 928551100 $12,006 2,317,814 SH Sole 1,2 2,317,814 Wyeth Common Stock 983024100 $120,418 2,725,000 SH Sole 1,2 2,725,000 Zymogenetics Common Stock 98985T109 $37,351 3,200,583 SH Sole 1,2 3,200,583 Inc.